CHANGE IN LEADERSHIP

Morten Gunvad, member of Aerocrine’s executive leadership team (Vice President Commercial Operations EU & ROW), will for personal reasons no longer hold employment with Aerocrine as per 31 October 2013. Aerocrine has agreed to transfer Aerocrine Europe GmbH, a fully owned Swiss subsidiary to Aerocrine AB, to Morten Gunvad in connection with his departure. The transfer falls within the scope of Chapter 16 of the Swedish Companies Act (the so-called Leo rules) and thus is subject to approval by the General Meeting of Aerocrine AB. The transfer is not expected to affect Aerocrine’s financial position. Aerocrine is in the process of forming a new subsidiary in Switzerland to maintain operations and for potential IP purposes. For further details, please be referred to the press release of the EGM notice to the shareholders of Aerocrine AB dated 27 September 2013.

For more information, contact: 
Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788 379 

About Aerocrine 
Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO®, which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com. 

Aerocrine is required to disclose the information provided herein pursuant to NASDAQ OMX Stockholm’s rulebook. The information was submitted for publication at 08:00 am on September 27, 2013.